Galectin Therapeutics Inc.
(Nasdaq: GALT), the leading developer of therapeutics that target galectin
proteins to treat fibrosis and cancer, today announced that the first patient
has been dosed in cohort 1 of the Company's Phase 1B clinical...
Startupbootcamp has just announced the first cohort of ten startups that will participate in the 2014 program of its London-based fintech accelerator. The startups that have made the cut for the inaugural three-month mentoring program include...
AURORA, ON -- (Marketwired) -- 07/15/14 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient...
(MedPage Today) -- Clinically depressed prostate cancer patients received definitive treatment less often and had worse survival as compared with patients without depression, data from a large cohort showed.
(MedPage Today) -- The risks of serious infections among patients with rheumatoid arthritis treated with anti-tumor necrosis factor agents were similar to those for patients given other types of biologics, a retrospective cohort study showed.
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.